Khosla Impact

Overture Life, Inc. is a biotechnology company established in 2017 and headquartered in New York, New York. The company specializes in developing robotic technology and medical devices aimed at automating the in vitro fertilization (IVF) process. Overture Life's innovations include novel embryo testing methodologies and automated cryopreservation services, which help fertility clinics identify viable embryos prior to implantation. By streamlining the IVF process, Overture Life aims to make artificial insemination more accessible, reduce costs, optimize resource use, and improve success rates for practitioners and patients alike.

Science is a startup company that develops technologies for a range of serious unmet medical needs.

Tempero Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment and prevention of substance use disorders. The company aims to address the challenges faced by individuals struggling with addiction, providing transformative solutions that help patients overcome treatment obstacles and support their recovery journey. Through its specialized approach, Tempero Bio is dedicated to improving the lives of those affected by substance use disorders and related conditions.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Enzymit is focused on transforming global manufacturing by advancing cell-free bio-production technology, which aims to reduce reliance on scarce resources and enhance sustainability. The company develops novel enzymes using artificial intelligence and deep learning algorithms, enabling the creation of innovative molecular machines that can convert abundant feedstocks into valuable products across various sectors, including pharmaceuticals, cosmetics, food, and materials. By employing small, modular bio-reactors, Enzymit enhances efficiency, reduces costs, and minimizes environmental impact compared to traditional whole-cell bio-production methods. This approach not only fosters resource independence but also allows for greater flexibility in product customization, positioning Enzymit as a competitive alternative to conventional chemical manufacturing.

Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, founded in 2016. The company specializes in developing rapid tests that assess the immune system to address significant clinical and public health challenges. Its primary focus is on creating diagnostics for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix employs proprietary machine-learning algorithms to analyze immune responses, producing clinically actionable results that support healthcare providers, particularly in emergency medicine, in making informed diagnostic decisions. Additionally, the company is building a diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and various other conditions.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By leveraging self-supervised learning and integrating human multimodal data, the company aims to enhance the effectiveness and personalization of cancer therapies, thereby improving patient outcomes in oncology.

Openwater is a San Francisco-based startup founded in 2016 that focuses on developing advanced medical technology aimed at diagnosing and treating diseases at the cellular level. The company has created a wearable device that leverages novel optoelectronic technology to offer high-resolution imaging capabilities, effectively replacing traditional MRI methods. By utilizing LCDs with small pixels, Openwater's device generates holographic images that minimize scattering and achieve MRI-like resolution. This innovation enables physicians to diagnose and treat diseases by targeting individual cells while preserving the surrounding tissue, thereby enhancing the precision and effectiveness of medical interventions.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in fields such as applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

YonedaLabs is a developer of AI-based software designed to assist chemists in optimizing various reaction parameters, including temperature, concentration, and catalysts. Their platform aims to enhance the efficiency of chemical laboratories by streamlining the process involved in drug and material production. By leveraging artificial intelligence, YonedaLabs enables businesses to accelerate their research and development efforts, ultimately improving outcomes in the field of chemistry.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies that target senescent cells responsible for various age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of innovative therapeutic candidates. These candidates include novel small molecules designed to selectively address senescent cells, which contribute to the progression of several chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises experienced professionals from the fields of chemistry, technology, and life sciences, bringing a wealth of knowledge in drug development and commercialization.

Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.

Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the lifespan and improving the health span of dogs. By creating medications that target the aging process, Loyal seeks to delay or prevent the onset of age-related diseases, including cancer, heart disease, and metabolic disorders. The company's innovative approach involves quantifying and regulating the biological processes associated with aging, which helps to mitigate the severity of these ailments. Through its research and product development, Loyal strives to ensure that dogs can enjoy longer, healthier lives, ultimately benefiting both pets and their owners.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Siolta Therapeutics, Inc. is a clinical-stage biotech company based in San Francisco, California, focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016, the company utilizes its expertise in the developing gut microbiome to promote immune tolerance. Siolta's platform includes the development of pharmaceutical-grade anaerobic organisms and microbiome-based diagnostics that support precision medicine. By leveraging insights from human microbiome studies, Siolta Therapeutics aims to create targeted microbial therapeutics that address the underlying causes of inflammatory diseases, enabling a new approach to prevention and treatment.

Sakana AI is a research-focused company dedicated to developing innovative foundation models inspired by nature. It specializes in creating an AI model capable of generating text, images, video, code, and multimedia, facilitating collaborative research and development in generative AI. The company's AI development process emphasizes evolution and collective intelligence.

Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company is creating a profiling and engineering technology platform that leverages advanced artificial intelligence to deliver an in-depth understanding of the epigenome in both health and disease. This innovative approach allows healthcare providers to explore new avenues for therapy discovery and facilitates the reprogramming of cells to restore their healthy state. By integrating AI-driven insights, Moonwalk Biosciences aims to transform the landscape of therapeutic development and improve patient outcomes.

Encellin, Inc. is a biotechnology company based in San Francisco, California, founded in 2015. It specializes in developing innovative cell-based therapeutics, particularly focusing on a novel thin-film cell encapsulation device. This device utilizes advanced thin-film cell delivery technology, which encapsulates and replaces cells, allowing the enclosed cells to operate as smart molecular factories. Encellin's primary mission is to provide effective treatments for patients with chronic diseases, with an initial emphasis on Type 1 diabetes. The company is committed to advancing next-generation therapies through the expertise of its dedicated team.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Vivodyne specializes in developing an automated robotic platform that aims to advance drug discovery and cellular therapies. The company's innovative microfluidic bioengineering technology facilitates the culture of highly realistic human tissue models, allowing researchers to explore complex biological processes. By employing single-cell 4D phenomics and integrating advanced imaging techniques, Vivodyne's system enables the formulation of tailored mixtures of compounds and cell therapies. This comprehensive approach not only accelerates the development of potential cures for various human diseases but also enhances the understanding of human health at a cellular level.

CellFE Inc. is a San Carlos, California-based company that specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. Founded in 2017, CellFE's innovative platform employs rapid cell compressions to enhance the uptake of therapeutic molecules from the surrounding fluid, facilitating the development and manufacturing of advanced cell therapies. This technology aims to address previously inaccessible cell therapies, enabling medical researchers to transport difficult-to-deliver molecules into cells for the treatment of various disorders, ultimately improving patient outcomes.

Rejuvenation Technologies Inc. is a biotechnology company based in Mountain View, California, focused on developing nucleoside-modified telomerase reverse transcriptase messenger RNA to extend telomeres and promote human health. The company's innovative approach involves delivering a telomere extender that encodes telomerase reverse transcriptase, which transiently boosts telomerase activity in cells. This technology aims to enhance the proliferative capacity of cells, potentially addressing age-related diseases and conditions in various medical fields, including hepatic, pulmonary, and immunology. Additionally, Rejuvenation Technologies offers a range of cell therapies that encompass tissue engineering, cell transplants, skin grafts, immunotherapy, and regenerative medicine. Established in 2016, the company is dedicated to advancing solutions in regenerative health.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

SURGE Therapeutics is dedicated to enhancing cancer patient survival through innovative approaches in immunotherapy. The company has developed a proprietary injectable biodegradable hydrogel designed for the prolonged and localized release of cancer immunotherapy following surgical tumor resection. By targeting the administration of treatment to specific areas at the optimal time, SURGE Therapeutics aims to improve the effectiveness of immunotherapy, allowing for both intravenous and intratumoral injections. This technology seeks to disrupt traditional cancer treatment paradigms and provide better outcomes for patients.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

Ceibo is an industrial biotechnology company dedicated to providing innovative solutions for the mining industry, particularly in the production of critical minerals essential for the clean energy transition. The company has developed proprietary technology for leaching copper sulfide, which enhances recovery from both primary and secondary sulfide ores rich in chalcopyrite. In addition to its leaching technology, Ceibo has implemented technologies aimed at dust suppression in mining operations. Currently, Ceibo operates within several large mining assets owned by prominent mining companies, focusing on optimizing processes, reducing costs, and promoting environmentally sustainable practices with a commitment to zero waste activity.

Tachyon Therapeutics is a biotechnology company focused on developing innovative therapeutics for cancer treatment. The firm specializes in creating selective compounds that target significant drug targets within cancer biology, employing advanced methodologies in molecular cancer biology, epigenetics, and cancer stem cell biology. Currently, Tachyon is conducting Phase 1 clinical trials to evaluate the safety, pharmacokinetics, and anti-tumor effectiveness of its lead compound, TACH101, in patients with advanced cancer. The company's research and development efforts aim to unlock new pathways for treating challenging cancer types, ensuring that its programs are advanced in a timely and scientifically rigorous manner.

IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.

Synchron is a medical technology company focused on developing innovative brain-computer interface solutions. It manufactures an implantable device known as the stentrode, which is delivered to the brain via a catheter. This minimally invasive device is embedded with electrode arrays that can interpret neuronal signals and modulate neural activity in targeted areas. By enabling patients with motor impairments to control digital devices, prosthetics, and other assistive technologies through thought, Synchron aims to enhance the quality of life for individuals with disabilities.

Bionaut Labs, Inc. is a biotechnology company based in Palo Alto, California, founded in 2016. The company specializes in developing a novel intra-tissue navigation platform utilizing Bionaut nano/micro robots that operate within the body. This innovative technology enables precise anatomical targeting for the treatment of central nervous system disorders, offering a new approach to precision medicine. By employing remote-controlled micro-robots, Bionaut Labs enhances the development of therapeutics, making advanced technologies like gene therapy and CRISPR-Cas9 feasible in challenging clinical scenarios. The Bionaut platform allows medical professionals to access any anatomic location within the body, facilitating the automation of complex procedures while eliminating the need for external incisions, thereby improving patient outcomes for those with limited treatment options.

SURGE Therapeutics is dedicated to enhancing cancer patient survival through innovative approaches in immunotherapy. The company has developed a proprietary injectable biodegradable hydrogel designed for the prolonged and localized release of cancer immunotherapy following surgical tumor resection. By targeting the administration of treatment to specific areas at the optimal time, SURGE Therapeutics aims to improve the effectiveness of immunotherapy, allowing for both intravenous and intratumoral injections. This technology seeks to disrupt traditional cancer treatment paradigms and provide better outcomes for patients.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.

Equii is a food technology company established in 2021 and located in San Ramon, California. Founded by Monica Bhatia, the company specializes in discovering and utilizing highly nutritious microbial proteins to enhance the fermentation of grains, resulting in high-protein grain flours. Equii's innovative approach transforms agricultural crops into nutritionally balanced products, catering to various eating occasions and providing consumers with access to healthier food options. Through its breakthrough technology, the company aims to deliver complete nutritional solutions, emphasizing the importance of protein-rich diets.

Carver Biosciences is a biotechnology firm specializing in the development of CRISPR/Cas13-based antiviral therapies. The company focuses on creating gene therapies that target RNA viruses, particularly respiratory viruses, at the RNA level. By utilizing the Cas13 technology, Carver aims to destroy these viruses and inhibit their replication. This approach is intended to complement existing vaccination efforts and viral inhibitors, providing patients with alternative treatment options to halt the progression of infections.

Arpeggio Bio, established in 2017 and headquartered in Boulder, Colorado, specializes in developing innovative software that captures snapshots of cellular RNA activity. By combining biological assays with advanced machine learning algorithms, the company enables pharmaceutical and biotechnology firms to understand a drug's mechanism of action at low sequencing depths. Arpeggio Bio's technology reveals intricate biological networks, facilitating more informed therapeutic development.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Genecis is an early-stage organic waste processing startup that uses biotechnology to convert waste into biodegradable plastics and other high-value materials. It converts organic waste into PHA (Polyhydroxyalkanoate), a biodegradable, compostable, and non-toxic polymer that can be tuned to replace a wide variety of traditional plastics. PHA can be used for single-use plastics, clothing and textiles, automotive interiors, medical tools and products, and food contact applications.

Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

CHARM Therapeutics is focused on developing innovative medicines using advanced 3D deep learning and drug discovery technologies. The company's platform aims to address undruggable disease targets, providing healthcare professionals with effective treatment options for challenging medical conditions. By leveraging cutting-edge technology, CHARM Therapeutics seeks to create transformative therapies that have the potential to significantly improve patient outcomes.

Anagenex is a seed stage biotechnology company focused on advancing drug discovery through its innovative platform. The company aims to tackle challenging pharmaceutical targets by utilizing a technology that combines machine learning with DNA-encoded libraries. This approach allows for the rapid analysis of compounds and the generation of extensive data sets, facilitating parallel biochemical experiments. By leveraging proprietary artificial intelligence models, Anagenex enables researchers to efficiently develop new small molecule drugs for medically significant applications.

Ultima Genomics, founded in 2016 and based in Newark, California, specializes in genome-scale sequencing technology aimed at providing analytical services to enterprises. The company employs an innovative approach using an open substrate that creates a large, low-cost reaction surface, allowing for billions of reads without the need for expensive flow cells or complex fluidics. By integrating specialized sequencing hardware with machine learning, Ultima Genomics ensures reproducible and accurate results, enabling clients to obtain genomic reports rapidly and efficiently. This technology not only enhances the scale of genomic information but also significantly reduces the costs associated with sequencing, thereby facilitating advancements in biology and improvements in human health.

Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

Mirvie is a biotech company focused on developing non-invasive tests aimed at improving maternal-fetal health. Founded in 2018 and based in South San Francisco, California, Mirvie offers a medical diagnostic platform that provides actionable insights for mothers and families throughout their pregnancy journey. The company's innovative predictive tests help medical practitioners identify at-risk pregnancies, allowing for timely interventions and enhanced management of pregnancy-related concerns. By prioritizing safety and health, Mirvie seeks to empower families with the information necessary for better pregnancy outcomes.

VitroLabs, Inc. is a startup based in San Jose, California, specializing in 3D tissue engineering and biomaterials. Founded in 2016, the company focuses on developing a scalable platform that utilizes advanced stem cell technologies to create authentic, lab-grown leather and other biomaterials. VitroLabs aims to provide a sustainable alternative to traditional animal-derived products, enabling fashion brands and interior designers to manufacture high-quality items without the ethical and environmental concerns associated with animal agriculture. By leveraging the latest advancements in stem cell research, VitroLabs is positioned at the forefront of innovation in the biomaterials industry.

Turn.bio is a biotechnology company focused on developing drugs aimed at reversing aging and age-related diseases. Leveraging its patented mRNA platform technology, known as ERA, the company addresses the effects of aging on the epigenome, thereby restoring optimal gene expression. Turn.bio’s innovative approach enables the body to heal itself by instructing specific cells to combat diseases or repair damaged tissues. The company targets a range of medical indications, including immune-related diseases such as cancer, dermatological conditions, ophthalmology, osteoarthritis, and issues related to the muscular system. Through its advanced delivery platform, eTurna, Turn.bio seeks to enhance the effectiveness of nucleic acid therapeutics in promoting health and longevity.

Volta Labs, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company specializes in developing tools for biological automation, focusing on scalable automation solutions for genetic engineering. Volta Labs operates a platform designed for affordable genomic sample preparation, aimed at revolutionizing genomics research. This platform leverages automation and miniaturization technologies to streamline the creation of biological samples. By integrating expertise from engineering, surface chemistry, and molecular biology, Volta Labs enables biotech organizations to automate complex biological workflows, facilitating advancements in genomics and genetic engineering.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Cellino is focused on creating an automated biomanufacturing system for personalized cell therapies, with the aim of making these treatments widely accessible. The company leverages an AI-guided laser editing platform that employs image-guided machine learning and robotics to generate autologous induced pluripotent stem cells (iPSCs) at scale. This innovative approach is designed to facilitate the development of potentially curative therapies for chronic degenerative diseases, such as vision loss and Parkinson's disease. By streamlining the process of cell therapy production, Cellino aims to enhance the availability of life-saving medicines for patients around the world.

Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.

Anagenex is a seed stage biotechnology company focused on advancing drug discovery through its innovative platform. The company aims to tackle challenging pharmaceutical targets by utilizing a technology that combines machine learning with DNA-encoded libraries. This approach allows for the rapid analysis of compounds and the generation of extensive data sets, facilitating parallel biochemical experiments. By leveraging proprietary artificial intelligence models, Anagenex enables researchers to efficiently develop new small molecule drugs for medically significant applications.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

NextVivo is a biotechnology company focused on advancing drug development through its innovative immune organoid technology platform. This platform generates human cell and antibody candidate therapies by harnessing the body's immune system. NextVivo's organoids are miniature 3D cell cultures designed to replicate the composition, structure, and function of human tissues, allowing for a realistic modeling of the humoral and cellular immune responses outside the body. This technology enables the testing of pre-clinical candidates on ex vivo human tissue models, facilitating the identification of the most effective therapies for clinical development. The company's mission is to accelerate the creation of safer and more effective treatments by utilizing immune-competent, human-derived models.

Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.

Fountain Therapeutics, Inc. is a biotechnology company focused on developing treatments for age-related diseases. Founded in 2018 and based in San Francisco, California, the company aims to create a future where individuals live healthier for longer. It employs a transformative cellular model that mimics the complex characteristics of aging within a laboratory setting. By integrating this model with advanced artificial intelligence and computer vision, Fountain Therapeutics seeks to establish an innovative platform for identifying novel therapeutic targets. This approach is designed to facilitate the development of effective treatments for diseases associated with aging, ultimately aiming to reverse cellular aging and improve health outcomes.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Vertical Oceans specializes in producing sustainable, same-day farm-to-fork shrimp using innovative vertical aquaculture towers located in major urban markets. The company employs a comprehensive system that integrates 83 technologies across bioengineering, hardware engineering, and computational engineering to enhance the seafood production process. Central to their operation is the Intelligent Habitat, or iHAB, which functions as a self-sustaining and self-cleaning modular production unit. This unique system incorporates a balanced aquatic ecosystem featuring fish and seaweed for biofiltration, promoting a more natural environment for shrimp cultivation. Vertical Oceans' approach allows for the delivery of fresh shrimp with strong sustainability credentials, while simultaneously eliminating the use of chemicals, antibiotics, and effluent.

Supplant is a biotechnology platform working in the food sector. It develops natural food ingredients from agricultural resources to allow food manufacturers to decrease sugar, increase fiber, and boost the gut health-promoting qualities of its products.

Pearl Bio is a synthetic biology company focused on advancing the field of biologics and biomaterials. It has developed a platform that incorporates genome engineering, ribosome engineering, and biomanufacturing techniques. This platform allows for the creation of innovative biomaterials and smart biologics, enabling researchers to enhance their understanding of gene function. Pearl Bio's work aims to facilitate the development of products and processes that can be utilized at a commercial scale, ultimately providing new avenues for treating genetic and acquired diseases.

VitroLabs, Inc. is a startup based in San Jose, California, specializing in 3D tissue engineering and biomaterials. Founded in 2016, the company focuses on developing a scalable platform that utilizes advanced stem cell technologies to create authentic, lab-grown leather and other biomaterials. VitroLabs aims to provide a sustainable alternative to traditional animal-derived products, enabling fashion brands and interior designers to manufacture high-quality items without the ethical and environmental concerns associated with animal agriculture. By leveraging the latest advancements in stem cell research, VitroLabs is positioned at the forefront of innovation in the biomaterials industry.

Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the lifespan and improving the health span of dogs. By creating medications that target the aging process, Loyal seeks to delay or prevent the onset of age-related diseases, including cancer, heart disease, and metabolic disorders. The company's innovative approach involves quantifying and regulating the biological processes associated with aging, which helps to mitigate the severity of these ailments. Through its research and product development, Loyal strives to ensure that dogs can enjoy longer, healthier lives, ultimately benefiting both pets and their owners.

Karma Biotechnologies, Inc. is a Los Angeles-based startup focused on developing therapies for autoimmune diseases, allergies, and food sensitivities. Founded in 2019, the company offers Xavines, a precision immunotherapy platform designed to address the critical need for antigen-specific therapies that target only the rogue immune cells responsible for these conditions. Unlike traditional treatments that rely on general immune suppression, Karma Biotechnologies aims to create tolerogenic immunotherapies that promote antigen-specific immune tolerance in vivo. By leveraging its expertise in immunology and lipid nanoparticle engineering, the company seeks to provide innovative solutions that enhance the treatment landscape for autoimmune diseases and related disorders.

Known Medicine Inc., founded in 2020 and based in Salt Lake City, Utah, specializes in developing a custom organoid platform designed for tumor sensitivity testing. The company aims to enhance cancer treatment by conducting experiments on tumor responses to drugs in a controlled laboratory setting rather than within the patient’s body. Known Medicine's innovative approach involves breaking down tumor samples into microtumors, which are treated in specialized micro-environments using various methods to identify the most effective treatments. The platform utilizes machine learning-based sensitivity assays and integrates omics data to detect different cell types, including cancerous, stromal, and immune cells. This enables oncologists to analyze multiple microtumors, ultimately helping to determine optimal treatment strategies for individual patients.

Encellin, Inc. is a biotechnology company based in San Francisco, California, founded in 2015. It specializes in developing innovative cell-based therapeutics, particularly focusing on a novel thin-film cell encapsulation device. This device utilizes advanced thin-film cell delivery technology, which encapsulates and replaces cells, allowing the enclosed cells to operate as smart molecular factories. Encellin's primary mission is to provide effective treatments for patients with chronic diseases, with an initial emphasis on Type 1 diabetes. The company is committed to advancing next-generation therapies through the expertise of its dedicated team.

Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.

IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.

Synchron is a medical technology company focused on developing innovative brain-computer interface solutions. It manufactures an implantable device known as the stentrode, which is delivered to the brain via a catheter. This minimally invasive device is embedded with electrode arrays that can interpret neuronal signals and modulate neural activity in targeted areas. By enabling patients with motor impairments to control digital devices, prosthetics, and other assistive technologies through thought, Synchron aims to enhance the quality of life for individuals with disabilities.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Overture Life, Inc. is a biotechnology company established in 2017 and headquartered in New York, New York. The company specializes in developing robotic technology and medical devices aimed at automating the in vitro fertilization (IVF) process. Overture Life's innovations include novel embryo testing methodologies and automated cryopreservation services, which help fertility clinics identify viable embryos prior to implantation. By streamlining the IVF process, Overture Life aims to make artificial insemination more accessible, reduce costs, optimize resource use, and improve success rates for practitioners and patients alike.

Apton Biosystems, Inc., founded in 2012 and located in Pleasanton, California, operates within the biotechnology industry, focusing on advanced medical technology. The company has developed an innovative optical system for sequencing and protein detection that utilizes super-resolution techniques. This technology allows for the assessment of molecules situated closer than the wavelength of light, facilitating multi-omic sequencing and single-molecule protein detection. Apton's solutions aim to enhance biomarker discovery, enable early disease detection, and support therapeutic monitoring, thereby contributing to advances in preventive health and precision medicine.

Turn.bio is a biotechnology company focused on developing drugs aimed at reversing aging and age-related diseases. Leveraging its patented mRNA platform technology, known as ERA, the company addresses the effects of aging on the epigenome, thereby restoring optimal gene expression. Turn.bio’s innovative approach enables the body to heal itself by instructing specific cells to combat diseases or repair damaged tissues. The company targets a range of medical indications, including immune-related diseases such as cancer, dermatological conditions, ophthalmology, osteoarthritis, and issues related to the muscular system. Through its advanced delivery platform, eTurna, Turn.bio seeks to enhance the effectiveness of nucleic acid therapeutics in promoting health and longevity.

Pendulum Therapeutics Inc. is a microbiome-focused company based in San Francisco that specializes in developing medical probiotics and prebiotics aimed at managing chronic illnesses, particularly type 2 diabetes. The company's flagship product, Pendulum Glucose Control, was introduced in 2020 and has demonstrated effectiveness in lowering blood sugar spikes and reducing A1C levels, as evidenced by published clinical trials. Pendulum utilizes evidence-based microbiome science and DNA sequencing to create targeted interventions, allowing clinicians to identify specific microbiome markers for disease treatment. Founded in 2013, Pendulum holds 13 patents and has 42 pending, with significant backing from prominent investors. The company sells its products online, focusing on improving healthcare through innovative microbiome therapies.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, founded in 2016. The company specializes in developing rapid tests that assess the immune system to address significant clinical and public health challenges. Its primary focus is on creating diagnostics for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix employs proprietary machine-learning algorithms to analyze immune responses, producing clinically actionable results that support healthcare providers, particularly in emergency medicine, in making informed diagnostic decisions. Additionally, the company is building a diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and various other conditions.

Bionaut Labs, Inc. is a biotechnology company based in Palo Alto, California, founded in 2016. The company specializes in developing a novel intra-tissue navigation platform utilizing Bionaut nano/micro robots that operate within the body. This innovative technology enables precise anatomical targeting for the treatment of central nervous system disorders, offering a new approach to precision medicine. By employing remote-controlled micro-robots, Bionaut Labs enhances the development of therapeutics, making advanced technologies like gene therapy and CRISPR-Cas9 feasible in challenging clinical scenarios. The Bionaut platform allows medical professionals to access any anatomic location within the body, facilitating the automation of complex procedures while eliminating the need for external incisions, thereby improving patient outcomes for those with limited treatment options.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Supplant is a biotechnology platform working in the food sector. It develops natural food ingredients from agricultural resources to allow food manufacturers to decrease sugar, increase fiber, and boost the gut health-promoting qualities of its products.

Cellino is focused on creating an automated biomanufacturing system for personalized cell therapies, with the aim of making these treatments widely accessible. The company leverages an AI-guided laser editing platform that employs image-guided machine learning and robotics to generate autologous induced pluripotent stem cells (iPSCs) at scale. This innovative approach is designed to facilitate the development of potentially curative therapies for chronic degenerative diseases, such as vision loss and Parkinson's disease. By streamlining the process of cell therapy production, Cellino aims to enhance the availability of life-saving medicines for patients around the world.

Ukko is a biotechnology company focused on enhancing the lives of individuals with food allergies and gluten-related disorders. Utilizing a sophisticated computational engineering platform, Ukko redesigns food allergens into therapeutics that are safe and effective. The company is developing a detailed, clinically validated map of the molecular structures associated with food allergies, which provides insights into the biological mechanisms of human-food interactions. By leveraging this information, Ukko creates modified proteins that do not provoke an immune response, offering a novel approach to treating protein-based allergies. Through the integration of artificial intelligence, immunology, computational biology, and protein engineering, Ukko aims to produce safe protein alternatives that physicians can confidently prescribe to patients.

Earli is a company focused on developing innovative cancer treatment devices that utilize synthetic biomarkers for early cancer detection. The company's approach involves a novel gene therapy technique known as Synthetic Biopsy, which prompts cancer cells to produce synthetic, non-human biomarkers. These biomarkers can be detected through various means, including blood, urine, or breath, allowing for timely tracking and treatment of cancer. By facilitating the early identification of cancer when it is still homogeneous, Earli aims to significantly enhance survival rates. Their technology not only aids in detection but is also applicable for therapeutic interventions, thereby personalizing treatment and improving patient outcomes.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies that target senescent cells responsible for various age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of innovative therapeutic candidates. These candidates include novel small molecules designed to selectively address senescent cells, which contribute to the progression of several chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises experienced professionals from the fields of chemistry, technology, and life sciences, bringing a wealth of knowledge in drug development and commercialization.

Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.

Siolta Therapeutics, Inc. is a clinical-stage biotech company based in San Francisco, California, focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016, the company utilizes its expertise in the developing gut microbiome to promote immune tolerance. Siolta's platform includes the development of pharmaceutical-grade anaerobic organisms and microbiome-based diagnostics that support precision medicine. By leveraging insights from human microbiome studies, Siolta Therapeutics aims to create targeted microbial therapeutics that address the underlying causes of inflammatory diseases, enabling a new approach to prevention and treatment.

Invoy is a company focused on providing personalized nutrition and wellness services through innovative monitoring medical devices. By utilizing science, data, and artificial intelligence, Invoy's technology captures real-time data on individual metabolism, allowing for tailored nutritional recommendations. The company aims to enhance individual health and weight loss goals by addressing the unique body chemistry of each person. With an emphasis on affordability, Invoy offers breath analyzers for medical applications, enabling users to effectively monitor their health and optimize their wellness journey.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.

Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

Menten AI, Inc. is an early-stage drug discovery company based in San Francisco, California, with an additional location in Toronto, Canada. Founded in 2018, the company focuses on developing protein-based drugs and enzymes using advanced technologies, specifically machine learning and quantum computing. Menten AI addresses the complex challenge of designing proteins, which can adopt numerous shapes, by leveraging quantum computing to represent multiple protein states simultaneously. This innovative approach allows for more efficient identification of optimal protein designs. The company has achieved significant milestones, including creating the world’s first peptide designed on a quantum computer, and is currently working on peptide therapeutics aimed at treating oncology and neurodegeneration, as well as enzymes for various industrial applications.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

E25Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing rapid diagnostic tests for epidemic fever viruses, including dengue, chikungunya, and Zika. Founded in 2018, the company specializes in paper-based diagnostic systems that enable swift detection of viral antigens produced during infections. Its innovative platform allows for real-time data reporting through a mobile application, which captures results along with information on test timing and location. This approach aims to facilitate epidemiologic predictions and disease mapping, ultimately assisting governments and health organizations in managing outbreaks effectively and preventing public health crises. E25Bio's solutions are designed to provide affordable and timely diagnostics at the point of care.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in fields such as applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Fountain Therapeutics, Inc. is a biotechnology company focused on developing treatments for age-related diseases. Founded in 2018 and based in San Francisco, California, the company aims to create a future where individuals live healthier for longer. It employs a transformative cellular model that mimics the complex characteristics of aging within a laboratory setting. By integrating this model with advanced artificial intelligence and computer vision, Fountain Therapeutics seeks to establish an innovative platform for identifying novel therapeutic targets. This approach is designed to facilitate the development of effective treatments for diseases associated with aging, ultimately aiming to reverse cellular aging and improve health outcomes.